Ethacrynic acid
From Wikipedia, the free encyclopedia
| Image:Ethacrynic acid.png | |
|
Ethacrynic acid
|
|
| Systematic (IUPAC) name | |
| 2-[2,3-dichloro-4-(2-methylidenebutanoyl) phenoxy] acetic acid | |
| Identifiers | |
| CAS number | 58-54-8 |
| ATC code | ? |
| PubChem | 3278 |
| DrugBank | APRD00251 |
| Chemical data | |
| Formula | C13H12Cl2O4 |
| Mol. weight | 303.137 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | > 98% |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Ethacrynic acid (Edecrin®) is a loop diuretic medication used to treat high blood pressure and the swelling caused by diseases like congestive heart failure, liver failure, and kidney failure.
[edit] Administration
25 mg and 50 mg tablets are available for oral use. The sodium salt (ethacrynate sodium) can also be given intravenously.
[edit] Side effects
As a diuretic, ethacrynic acid can cause frequent urination, but this usually resolves after taking the drug for a few weeks.
Ethacrynic acid can also cause low potassium levels, which may manifest as muscle cramps or weakness.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
